app.rxdatalab.com · Free public feature

Regulatory filings linked to clinical programs and markets. Trials, SEC filings, insider activity, and market data from primary sources.

Get Full Access Today → Login →

BioHedge

Hedge fund positioning from Schedule 13D/13G filings. Each position cross-referenced with clinical trial events, regulatory filings, and insider trades.

Filings through Mar 19, 2026

Updated continuously

Weekly recaps → Strategic Signals → What are these? ↓

Activity Summary

Last 60 Days

13D Filings

New Positions

Exits

Increased

Decreased

Funds Active

Multi-Fund Activity

Companies with two or more institutional investors filing in the same period.

Accumulating

SABS SAB BIOTHERAPEUTICS INC

▲6.4

3 funds

RA Capital Management , BVF Partners L.P. ▼-0.9 , Perceptive Advisors ▲7.3

XNCR Xencor Inc

▲3.5

2 funds

BVF Partners L.P. ▲3.5 , EcoR1 Capital

TENX TENAX THERAPEUTICS, INC.

▲2.1

2 funds

BVF Partners L.P. , Perceptive Advisors ▲2.1

IVVD INVIVYD INC

▲1.6

2 funds

RA Capital Management , BVF Partners L.P. ▲1.6

Reducing

AVTX Avalo Therapeutics, Inc.

▼-2.5

3 funds

RA Capital Management, BVF Partners L.P., OrbiMed ▼-2.5

TNGX Tango Therapeutics, Inc.

▼-11.0

2 funds

EcoR1 Capital ▼-9.9, Third Rock Ventures ▼-1.1

TYRA Tyra Biosciences, Inc.

▼-5.0

2 funds

RA Capital Management ▼-1.2, BVF Partners L.P. ▼-3.8

GLUE Monte Rosa Therapeutics, Inc.

▼-3.3

2 funds

Baker Brothers Advisors, BVF Partners L.P. ▼-3.3

SLDB Solid Biosciences Inc.

▼-2.7

2 funds

RA Capital Management, Perceptive Advisors ▼-2.7

Filing Volume by Week

13D 13G

Period:

Sort:

Filed	Fund	Company	Position	Gap
Mar 19, 2026 Event: 03/12/2026 Filed: Mar 19, 2026	G Perceptive Advisors	RLAY Relay Therapeutics, Inc.	owns 5.3% NEW	—
G Perceptive Advisors Mar 19, 2026 RLAY Relay Therapeutics, Inc. 5.3% NEW
Mar 17, 2026 Event: 03/13/2026 Filed: Mar 17, 2026	D RA Capital Management	SLDB Solid Biosciences Inc.	owns 9.9%	—
D RA Capital Management Mar 17, 2026 SLDB Solid Biosciences Inc. 9.9%
Mar 17, 2026 Event: 03/13/2026 Filed: Mar 17, 2026	D RA Capital Management	ABOS Acumen Pharmaceuticals, Inc.	owns 29.5%	—
D RA Capital Management Mar 17, 2026 ABOS Acumen Pharmaceuticals, Inc. 29.5%
Mar 16, 2026 Event: 03/12/2026 Filed: Mar 16, 2026	D RA Capital Management	VOR Vor Biopharma Inc.	owns 19.9%	—
D RA Capital Management Mar 16, 2026 VOR Vor Biopharma Inc. 19.9%
Mar 11, 2026 Event: 03/09/2026 Filed: Mar 11, 2026	D Perceptive Advisors	SLDB Solid Biosciences Inc.	owns 12.9% ▼-2.7	383d
D Perceptive Advisors Mar 11, 2026 SLDB Solid Biosciences Inc. 12.9% ▼-2.7 383d
Mar 11, 2026 Event: 03/09/2026 Filed: Mar 11, 2026	D RA Capital Management	SABS SAB BIOTHERAPEUTICS INC	owns 9.9%	159d
D RA Capital Management Mar 11, 2026 SABS SAB BIOTHERAPEUTICS INC 9.9% 159d
Mar 10, 2026 Event: 03/06/2026 Filed: Mar 10, 2026	D RA Capital Management	SLDB Solid Biosciences Inc.	owns 9.9%	208d
D RA Capital Management Mar 10, 2026 SLDB Solid Biosciences Inc. 9.9% 208d
Mar 6, 2026 Event: 03/04/2026 Filed: Mar 6, 2026	D RA Capital Management	TYRA Tyra Biosciences, Inc.	owns 21.2% ▼-1.2	273d
D RA Capital Management Mar 6, 2026 TYRA Tyra Biosciences, Inc. 21.2% ▼-1.2 273d
Mar 4, 2026 Event: 03/02/2026 Filed: Mar 4, 2026	D OrbiMed	PMVP PMV Pharmaceuticals, Inc.	owns 0.0% EXIT	128d
D OrbiMed Mar 4, 2026 PMVP PMV Pharmaceuticals, Inc. 0.0% EXIT 128d
Mar 2, 2026 Event: 02/26/2026 Filed: Mar 2, 2026	D RA Capital Management	BCAX Bicara Therapeutics	owns 11.5%	—
D RA Capital Management Mar 2, 2026 BCAX Bicara Therapeutics 11.5%
Mar 2, 2026 Event: 02/27/2026 Filed: Mar 2, 2026	D Deerfield Management	LRMR Larimar Therapeutics, Inc.	owns 34.4% ▼-1.4	214d
D Deerfield Management Mar 2, 2026 LRMR Larimar Therapeutics, Inc. 34.4% ▼-1.4 214d
Feb 27, 2026 Event: 02/25/2026 Filed: Feb 27, 2026	D 5AM Ventures	RLYB Rallybio Corp	owns 5.5%	—
D 5AM Ventures Feb 27, 2026 RLYB Rallybio Corp 5.5%
Feb 26, 2026 Event: 02/24/2026 Filed: Feb 26, 2026	D Baker Brothers Advisors	ACAD ACADIA PHARMACEUTICALS INC	owns 25.4%	—
D Baker Brothers Advisors Feb 26, 2026 ACAD ACADIA PHARMACEUTICALS INC 25.4%
Feb 23, 2026 Event: 02/20/2026 Filed: Feb 23, 2026	D BIOS Partners	LTRN Lantern Pharma Inc.	owns 8.6% ▼-1.4	255d
D BIOS Partners Feb 23, 2026 LTRN Lantern Pharma Inc. 8.6% ▼-1.4 255d
Feb 20, 2026 Event: 02/12/2026 Filed: Feb 20, 2026	D BVF Partners L.P.	IMUX IMMUNIC INC	owns 10.0% NEW	190d
D BVF Partners L.P. Feb 20, 2026 IMUX IMMUNIC INC 10.0% NEW 190d
Feb 18, 2026 Event: 02/10/2026 Filed: Feb 18, 2026	G BVF Partners L.P.	STRO SUTRO BIOPHARMA, INC.	owns 7.6% NEW	—
G BVF Partners L.P. Feb 18, 2026 STRO SUTRO BIOPHARMA, INC. 7.6% NEW
Feb 17, 2026 Event: 12/31/2025 Filed: Feb 17, 2026	G Baker Brothers Advisors	ALKS Alkermes plc.	owns 6.1% NEW	—
G Baker Brothers Advisors Feb 17, 2026 ALKS Alkermes plc. 6.1% NEW
Feb 17, 2026 Event: 12/31/2025 Filed: Feb 17, 2026	G MPM BioImpact	CLYM CLIMB BIO INC	owns 5.6% NEW	—
G MPM BioImpact Feb 17, 2026 CLYM CLIMB BIO INC 5.6% NEW
Feb 17, 2026 Event: 12/31/2025 Filed: Feb 17, 2026	G MPM BioImpact	DBVT DBV Technologies S.A.	owns 9.9% NEW	—
G MPM BioImpact Feb 17, 2026 DBVT DBV Technologies S.A. 9.9% NEW
Feb 17, 2026 Event: 12/31/2025 Filed: Feb 17, 2026	G Cormorant Asset Management, LP	MLTX MoonLake Immunotherapeutics	owns 6.1% NEW	—
G Cormorant Asset Management, LP Feb 17, 2026 MLTX MoonLake Immunotherapeutics 6.1% NEW
Feb 17, 2026 Event: 12/31/2025 Filed: Feb 17, 2026	G Cormorant Asset Management, LP	ENGN enGene, Inc.	owns 6.0% NEW	—
G Cormorant Asset Management, LP Feb 17, 2026 ENGN enGene, Inc. 6.0% NEW
Feb 17, 2026 Event: 12/31/2025 Filed: Feb 17, 2026	G RA Capital Management	FDMT 4D Molecular Therapeutics, Inc.	owns 9.9%	368d
G RA Capital Management Feb 17, 2026 FDMT 4D Molecular Therapeutics, Inc. 9.9% 368d
Feb 17, 2026 Event: 12/31/2025 Filed: Feb 17, 2026	G BVF Partners L.P.	FDMT 4D Molecular Therapeutics, Inc.	owns 10.0%	278d
G BVF Partners L.P. Feb 17, 2026 FDMT 4D Molecular Therapeutics, Inc. 10.0% 278d
Feb 17, 2026 Event: 12/31/2025 Filed: Feb 17, 2026	G Baker Brothers Advisors	GLUE Monte Rosa Therapeutics, Inc.	owns 6.7%	—
G Baker Brothers Advisors Feb 17, 2026 GLUE Monte Rosa Therapeutics, Inc. 6.7%
Feb 17, 2026 Event: 12/31/2025 Filed: Feb 17, 2026	G BVF Partners L.P.	GLUE Monte Rosa Therapeutics, Inc.	owns 5.9% ▼-3.3	278d
G BVF Partners L.P. Feb 17, 2026 GLUE Monte Rosa Therapeutics, Inc. 5.9% ▼-3.3 278d

Understanding Schedule 13D and 13G Filings

Schedule 13D and 13G filings are SEC disclosures required when an investor acquires more than 5% of a company's outstanding shares.

Schedule 13D (Activist)

Filed when an investor may seek to influence management, board composition, or corporate strategy. Requires disclosure of investment purpose and plans.

Schedule 13G (Passive)

Filed by passive investors (mutual funds, index funds, institutions) with no intent to influence. Simpler filing requirements.

Gap column: Days since previous filing for the same fund+company pair.

Data source: SEC EDGAR. Filings typically available within 4 hours of submission.

This page reflects disclosed ownership changes only. Absence of activity does not imply absence of interest.

Intelligence Platform

Every event, in context.

Cross-reference each company's trial history, SEC filings, insider trades, and fund positioning in one view. Traceable to primary sources.

See the Platform → or email [email protected]